Orexo’s annual report for 2014 released
Orexo’s annual report for the 2014 fiscal year has been published and can be downloaded from the investor section of the company’s homepage www.orexo.com/ar/2014/en/ .
For further information, please contact:
Beata Augenblick, Investor Relations
Tel: +46-18 780 88 50, E-mail: firstname.lastname@example.org
Orexo is an integrated pharmaceutical company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery. The company is commercializing its proprietary product, Zubsolv® sublingual tablets, for maintenance treatment of opioid dependence, in the United States. The Zubsolv sublingual tablet is a novel formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the US, EU and Japan. Orexo AB, with its headquarters in Sweden, is listed on Nasdaq Stockholm Exchange (STO: ORX) and its American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the U.S. under the symbol, “ORXOY”. The largest shareholders are Novo A/S and HealthCap.
For information about Orexo, please visit www.orexo.com
Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Markets Act. The information was submitted for publication at 9:30am CET on March 25, 2015.